See more : Phoenix Pioneer technology Co., Ltd. (6920.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Mangoceuticals, Inc. (MGRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mangoceuticals, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Sigmastar Technology Ltd. (301536.SZ) Income Statement Analysis – Financial Results
- Medivolve Inc. (4NC.F) Income Statement Analysis – Financial Results
- SLANG Worldwide Inc. (SLNG.CN) Income Statement Analysis – Financial Results
- Cymat Technologies Ltd. (CYMHF) Income Statement Analysis – Financial Results
- FIPP S.A. (FIPP.PA) Income Statement Analysis – Financial Results
Mangoceuticals, Inc. (MGRX)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.mangorx.com
About Mangoceuticals, Inc.
Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.
| Metric | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 731.49K | 8.94K | 0.00 |
| Cost of Revenue | 299.99K | 4.09K | 0.00 |
| Gross Profit | 431.50K | 4.85K | 0.00 |
| Gross Profit Ratio | 58.99% | 54.26% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.45M | 2.00M | 70.08K |
| Selling & Marketing | 2.10M | 352.86K | -52.56K |
| SG&A | 8.55M | 2.00M | 17.52K |
| Other Expenses | 1.10M | 0.00 | 0.00 |
| Operating Expenses | 9.65M | 2.00M | 17.52K |
| Cost & Expenses | 9.95M | 2.00M | 17.52K |
| Interest Income | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.47K | 181.00 |
| Depreciation & Amortization | 24.89K | 3.86K | 70.08K |
| EBITDA | -9.19M | -1.99M | 52.56K |
| EBITDA Ratio | -1,256.00% | -22,236.48% | 0.00% |
| Operating Income | -9.22M | -1.99M | -17.52K |
| Operating Income Ratio | -1,260.28% | -22,279.70% | 0.00% |
| Total Other Income/Expenses | 6.47K | -6.47K | -53.28K |
| Income Before Tax | -9.21M | -2.00M | -17.70K |
| Income Before Tax Ratio | -1,259.40% | -22,352.11% | 0.00% |
| Income Tax Expense | 0.00 | -224.62K | -70.08K |
| Net Income | -9.21M | -2.00M | -17.70K |
| Net Income Ratio | -1,259.40% | -22,352.11% | 0.00% |
| EPS | -6.45 | -0.12 | 0.00 |
| EPS Diluted | -6.45 | -0.12 | 0.00 |
| Weighted Avg Shares Out | 1.43M | 17.32M | 17.32M |
| Weighted Avg Shares Out (Dil) | 1.43M | 17.32M | 17.32M |
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
Dallas, Texas, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform learned earlier this morning that Eli...
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
Dallas, Texas--(Newsfile Corp. - October 18, 2024) - Mangoceuticals, Inc. (NASDAQ: MGRX), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform,, is pleased to announce it will be presenting at the...
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
DALLAS, TX, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction (ED), hair...
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
Dallas, Texas, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling men's health and wellness products via a secure telemedicine platform, announces the release of its latest...
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss category
MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024
Dallas, Texas, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the area of erectile dysfunction...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair...
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian Market
Dallas, TX Based Men's Health Telemedicine Company Announces Successful Participation in Beijing Exhibit DALLAS, TX / ACCESSWIRE / August 8, 2024 / Mangoceuticals, Inc. (NASDAQ:MGRX) ("MangoRx" or the "Company"), a leader in developing, marketing, and selling a variety of men's...
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention Technology
Dallas, Texas, July 24, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“ MangoRx ” or the “Company”), a leader in men's health and wellness products including erectile dysfunction (ED), hair growth, weight loss, and hormone replacement therapies, is excited...
Mangoceuticals CEO Jacob Cohen Featured on Benzinga All-Access
DALLAS, TEXAS, July 18, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("MangoRx" or the "Company”), a company focused on developing, marketing, and selling a variety of men's health and wellness products in the areas of erectile dysfunction (ED), hair...
Source: https://incomestatements.info
Category: Stock Reports